Has Rekha Kini, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,722 in general payments to Rekha Kini, MD across 78 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rekha Kini, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rekha Kini, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rekha Kini, MD

Internal Medicine · Miami, FLNPI 1902974454

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novo Nordisk at 24.8% of the total. 2025 is the largest year on record at $520, 5.4 times the $97 reported in 2019.

$1,722in general payments, 2019–2025

Across 78 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$427
AstraZeneca$204
Pfizer$204
Lilly USA, LLC$196
Exact Sciences$133
Currax Pharmaceuticals LLC$94
plus $463 from 15 others

What the payments were for

Food & beverage$1,722100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	20	$427
AstraZeneca	4	$204
Pfizer	9	$204
Lilly USA, LLC	11	$196
Exact Sciences	6	$133
Currax Pharmaceuticals LLC	6	$94
Bausch Health US, LLC	4	$73
Eisai Inc.	2	$47
Idorsia Pharmaceuticals US Inc	2	$44
Sanofi Pasteur Inc.	2	$42
Takeda Pharmaceuticals U.S.A., Inc.	2	$39
BD	1	$33
Ironwood Pharmaceuticals, Inc	1	$27
GSK	1	$23
AbbVie	1	$22
Phadia US Inc.	1	$21
Merck	1	$20
Bard Peripheral Vascular, Inc.	1	$19
Astellas Pharma US Inc	1	$19
Otsuka America Pharmaceutical, Inc.	1	$18
Nalpropion Pharmaceuticals LLC	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

AIRSUPRA$129

How this compares

$1,722 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida →

Medicare billing

Part B allowed, 2024

$27,751

Medicare patients

110

Services billed

389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Rosuvastatin Calcium	43	$721
Omeprazole	28	$657
Atorvastatin Calcium	35	$421
Losartan Potassium	46	$336
Levothyroxine Sodium	39	$284
Amlodipine Besylate	23	$245
Gabapentin	17	$238
Zolpidem Tartrate	17	$187
Alprazolam	25	$155
Metformin Hcl	26	$128
Clonazepam	12	$125
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide	15	$123
Lorazepam	14	$103
Lisinopril	26	$96
Sertraline Hcl	21	$49

Paid to pharmacies, not to this prescriber.

Other internal medicine in Miami

Haytham ElgammalMiami$2.2M
Richard AguilarMiami$239K
Maria Delgado LelievreMiami$80K
Marlow HernandezMiami$58K
Steven CohnMiami$47K
Joseph PiperatoMiami$45K
Simon AbelsonMiami$44K
Joel Brooks TamayoMiami$42K
Keith RubinFort Lauderdale$2M
Michael SensionFort Lauderdale$1M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →